Novel responses of human skin to intradermal recombinant granulocyte/macrophage-colony-stimulating factor: Langerhans cell recruitment, keratinocyte growth, and enhanced wound healing
- PMID: 1588289
- PMCID: PMC2119267
- DOI: 10.1084/jem.175.6.1717
Novel responses of human skin to intradermal recombinant granulocyte/macrophage-colony-stimulating factor: Langerhans cell recruitment, keratinocyte growth, and enhanced wound healing
Abstract
Recombinant granulocyte/macrophage-colony-stimulating factor (rGM-CSF), prepared from Chinese hamster ovary (CHO) cells and Escherichia coli, was administered to 35 patients with the borderline and polar lepromatous forms of leprosy by the intradermal and subcutaneous routes at doses of 7.5-45.0 micrograms/d for 10 d. With each of these doses and routes, increases in the number of circulating eosinophils were noted. After the intradermal injection, the local skin sites demonstrated zones of roughening and micronodularity that appeared within 24-48 h and persisted for more than 6 d. Reinjection of sites led to enhanced areas of epidermal reaction. GM-CSF prepared from CHO cells was a more potent inducer of this effect. GM-CSF given by the subcutaneous route, at higher doses, failed to initiate these changes. At the microscopic level, the epidermis became thickened (+75%) with increased numbers and layers of enlarged keratinocytes. These contained increased numbers of ribosomes and prominent nucleoli, and were imbedded in a looser meshwork of the zona Pellucida. The modified keratinocytes remained MHC class II antigen negative throughout the course of the response. A major change in the dermis was the progressive accumulation of CD1+, Birbeck granule-positive cells. These Langerhans were recognizable at 48 h after intradermal injection and reached maximum numbers by 4 d. During this period the number of epidermal Langerhans cells remained relatively constant. No increment in dermal Langerhans cells occurred when GLM-CSF was injected by the subcutaneous route. No appreciable increase in the numbers of T cells and monocytes was noted, and granulocytes and eosinophils were largely present within the dermal microvasculature. 4-mm punch biopsies taken from injected sites and adjacent controls were compared in terms of the rapidity of wound healing. 22 of 26 sites demonstrated more rapid filling and hemostasis, whereas four were equivalent to controls. We conclude that rGM-CSF, when introduced into the skin, leads to enhanced keratinocyte growth, the selective recruitment of Langerhans cells into the dermis, and enhanced wound healing of the prepared site. There was no evidence of an enhanced cell-mediated response to Mycobacterium leprae, and bacillary numbers remained unchanged.
Similar articles
-
Effect of granulocyte macrophage-colony stimulating factor on Langerhans cells in normal and healthy atopic subjects.Br J Dermatol. 1998 Aug;139(2):239-46. doi: 10.1046/j.1365-2133.1998.02360.x. Br J Dermatol. 1998. PMID: 9767237
-
GM-CSF activates regenerative epidermal growth and stimulates keratinocyte proliferation in human skin in vivo.J Invest Dermatol. 1994 Oct;103(4):601-4. doi: 10.1111/1523-1747.ep12396936. J Invest Dermatol. 1994. PMID: 7930689
-
Cellular responses to the intradermal injection of recombinant human gamma-interferon in lepromatous leprosy patients.Am J Pathol. 1987 Aug;128(2):345-53. Am J Pathol. 1987. PMID: 3113256 Free PMC article.
-
Practical Application of Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Patients with Wounds.Surg Technol Int. 2018 Jun 1;32:61-66. Surg Technol Int. 2018. PMID: 29611156 Review.
-
Pathology of recombinant human transforming growth factor-beta 1 in rats and rabbits.Int Rev Exp Pathol. 1993;34 Pt B:43-67. doi: 10.1016/b978-0-12-364935-5.50009-2. Int Rev Exp Pathol. 1993. PMID: 8458717 Review.
Cited by
-
The Roles of Growth Factors in Keratinocyte Migration.Adv Wound Care (New Rochelle). 2015 Apr 1;4(4):213-224. doi: 10.1089/wound.2014.0540. Adv Wound Care (New Rochelle). 2015. PMID: 25945284 Free PMC article. Review.
-
New insights into the mobilization and phagocytic activity of dendritic cells.J Exp Med. 1996 Apr 1;183(4):1287-92. doi: 10.1084/jem.183.4.1287. J Exp Med. 1996. PMID: 8666885 Free PMC article. No abstract available.
-
Phase I/II study of GM-CSF DNA as an adjuvant for a multipeptide cancer vaccine in patients with advanced melanoma.Mol Ther. 2008 Dec;16(12):2022-9. doi: 10.1038/mt.2008.196. Epub 2008 Sep 16. Mol Ther. 2008. PMID: 18797450 Free PMC article. Clinical Trial.
-
Immunotherapeutic approaches for the treatment of breast cancer.J Mammary Gland Biol Neoplasia. 1999 Oct;4(4):353-65. doi: 10.1023/a:1018714300217. J Mammary Gland Biol Neoplasia. 1999. PMID: 10705919 Review.
-
Colonization of in vitro-formed cervical human papillomavirus- associated (pre)neoplastic lesions with dendritic cells: role of granulocyte/macrophage colony-stimulating factor.Am J Pathol. 1999 Mar;154(3):775-84. doi: 10.1016/S0002-9440(10)65324-2. Am J Pathol. 1999. PMID: 10079255 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials